Rhumbline Advisers Has $12.91 Million Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Rhumbline Advisers decreased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 7.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 150,162 shares of the company's stock after selling 11,329 shares during the period. Rhumbline Advisers owned about 0.30% of Prestige Consumer Healthcare worth $12,909,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in PBH. Kestra Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC boosted its holdings in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC acquired a new position in Prestige Consumer Healthcare in the 4th quarter valued at about $40,000. McIlrath & Eck LLC increased its stake in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares during the period. Finally, Johnson Financial Group Inc. acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth approximately $93,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on the company. Oppenheimer upped their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, May 17th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of PBH traded down $0.04 during trading hours on Thursday, reaching $85.08. The stock had a trading volume of 278,537 shares, compared to its average volume of 299,363. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. Prestige Consumer Healthcare Inc. has a 12 month low of $63.79 and a 12 month high of $90.04. The stock has a market capitalization of $4.20 billion, a PE ratio of 19.93, a PEG ratio of 2.69 and a beta of 0.45. The company's 50-day moving average is $83.61 and its two-hundred day moving average is $82.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company had revenue of $296.52 million for the quarter, compared to analysts' expectations of $289.36 million. During the same period in the previous year, the business posted $1.02 earnings per share. The business's quarterly revenue was up 7.0% compared to the same quarter last year. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.